Agilon Health (NYSE:AGL) Price Target Raised to $13.00 at Benchmark

Agilon Health (NYSE:AGL) had its target price lifted by Benchmark to $13.00 in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

AGL has been the subject of several other research reports. Wells Fargo & Company increased their price objective on shares of Agilon Health from $25.00 to $37.50 and gave the company an “overweight” rating in a research note on Friday, February 27th. Citigroup cut their target price on shares of Agilon Health from $21.25 to $18.75 and set a “neutral” rating on the stock in a research note on Tuesday, March 3rd. Barclays reduced their target price on shares of Agilon Health from $25.00 to $12.50 and set an “underweight” rating for the company in a research note on Friday, February 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Finally, Royal Bank Of Canada upgraded shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $51.93.

Agilon Health Trading Up 9.3%

Shares of AGL stock opened at $10.66 on Thursday. The stock has a market cap of $176.87 million, a P/E ratio of -0.45 and a beta of 0.33. Agilon Health has a 1 year low of $7.48 and a 1 year high of $152.00. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. The stock has a 50 day simple moving average of $13.97 and a 200 day simple moving average of $18.53.

Agilon Health (NYSE:AGL) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%.The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.46 billion. On average, research analysts predict that Agilon Health will post -0.59 earnings per share for the current fiscal year.

Institutional Trading of Agilon Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wealthcare Advisory Partners LLC purchased a new position in Agilon Health in the 3rd quarter worth $26,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Agilon Health during the third quarter valued at approximately $34,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Agilon Health during the third quarter valued at approximately $37,000. Tower Research Capital LLC TRC increased its position in shares of Agilon Health by 214.0% in the second quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock valued at $85,000 after acquiring an additional 25,270 shares during the period. Finally, Independent Advisor Alliance bought a new stake in Agilon Health in the third quarter valued at $39,000.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.